Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Videos|July 31, 2026
Palforzia Discontinued, Ending the Only FDA-Approved Peanut OIT Option
Author(s)Robert Wood, MD, Jacqueline Ross, MD
Fact checked by: Chelsie Derman
As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.
Advertisement
Advertisement
Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia), the first and only FDA-approved oral immunotherapy (OIT) for
Related to this article
On World Psoriasis Day, advocates Nitika Chopra and Ayesha Patrick discuss feeling dismissed and what dermatologists should know about skin of color care.
Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.
Jean Elwing, MD, and pulmonologists from across the US discuss how risk, payer coverage, and patient resources shape PAH therapy selection.
In the SCENARIO trial, a 15-week weight-loss program cut recurrent vascular events by 67% in patients with obesity after minor ischemic stroke or TIA.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.
Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.
Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.
Advertisement
Advertisement